Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia

CONCLUSIONS: These results highlight TIM-4-L as a highly prevalent target on AML across a range of genetic classifications and novel target for T cell-based therapy in AML. Further investigations into the role of TIM-4-L in AML pathogenesis and its potential as an anti-leukemic target for clinical development are warranted.PMID:38451195 | DOI:10.1158/1078-0432.CCR-23-3044

Source: Clinical Cancer Research - March 7, 2024 Category: Cancer & Oncology Authors: Brandon Cieniewicz Edson Oliveira Mike Saxton Damoun Torabi Ankit Bhatta Phanidhar Kukutla Alexander Arballo Zhuo Yang Bi Yu Maria Fate Hongxiu Ning Lawrence Corey Abhishek Maiti Daniel Corey Source Type: research